Are you living with chronic kidney disease?

If you are at least 18 years of age and referred for arteriovenous fistula creation surgery, you may be eligible for SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study

Learn About the Trial

Standard of Care

Arteriovenous fistulas are the standard of care in hemodialysis. Unfortunately, they have a 50 - 60% 1-year failure rate, resulting in catheter reliance, interventions, and many other complications that adversely impact patients.

Our Goal

At VenoStent, we are working to improve the usability and durability of AVFs for more reliable dialysis. This could have a positive impact on patient care and quality of life for chronic kidney disease (CKD) patients.

Remuneration

If you are eligible for this trial and elect to participate, you will be compensated for your participation. Ask your doctor for more details.

Latest Updates

Oct 31, 2025Many thanks and congratulations to Dr. Colby Atkins, the Surgical Associates of Lexington research team (Amanda Gaddis, APRN and Kelly Dickerson), and the OR Team at St Joseph’s Hospital for their first randomizations in SAVE-FistulaS!

Dec 11, 2024Congratulations Christopher Griggs and Robert Heidepriem and Tallahassee Research Institute at Tallahassee Memorial HealthCare. First patient in Florida enrolled in the SAVE-FistulaS Clinical Trial.

Nov 7, 2024Congratulations to PI Dr. Mohamed Hussain, subinvestigator Dr. Omar Selim, study coordinators Danielle Moreno-Montano and Navya Kotturu, and the rest of the study team at Brigham and Women's Hospital for their first randomizations in the SAVE-FistulaS study!

See all updates

clinicaltrials.gov: NCT06001827

SelfWrap is currently in the research and development phase and is not available for sale in any country. Investigational device. Limited by federal law to investigational use.